ovarian neoplasm epithelial
Showing 1 - 9 of 9
Ovarian Tumor Epithelial Trial (acute normovolemic hemodilution (ANH), acute hypervolemic hemodilution (AHH))
Completed
- Ovarian Neoplasm Epithelial
- acute normovolemic hemodilution (ANH)
- acute hypervolemic hemodilution (AHH)
- (no location specified)
Oct 21, 2023
Ovarian Cancer, Ovarian Tumor, Ovarian Tumor Epithelial Trial (MIRRORS Protocol, Standard Open Cytoreductive Surgery)
Not yet recruiting
- Ovarian Cancer
- +5 more
- MIRRORS Protocol
- Standard Open Cytoreductive Surgery
- (no location specified)
Jul 17, 2023
Ovarian Tumor Epithelial, Ovarian Cancer, Fallopian Tube Tumors Trial in India (Oregovomab, Paclitaxel, Carboplatin)
Not yet recruiting
- Ovarian Neoplasm Epithelial
- +4 more
- Oregovomab
- +3 more
-
Visakhapatnam, Andhra Pradesh, India
- +7 more
Dec 7, 2022
Sub-type Specific Genomic Mutations in sBOTs
Recruiting
- Ovarian Neoplasm Epithelial
- genomic mutations study
-
Jette, Brussels, BelgiumUniversitair Ziekenhuis UZBrussel
Oct 18, 2021
Ovarian Tumor Epithelial, Homologous Recombination Deficiency, BRCA1 Mutation Trial in Groningen, Leiden, Rotterdam (Functional
Recruiting
- Ovarian Neoplasm Epithelial
- +3 more
- Functional RAD51 assay
- Olaparib Oral Product
-
Groningen, Netherlands
- +2 more
Mar 30, 2021
Minimally Invasive Robotic Surgery, Role in Optimal Debulking
Recruiting
- Ovarian Cancer
- +4 more
- Robotic Interval Debulking Surgery
-
Guildford, Surrey, United KingdomRoyal Surrey NHS Foundation Trust
Aug 31, 2020
Ovarian Tumor Epithelial, High Grade Serous Carcinoma Trial in Seongnam Si (Pegylated liposomal doxorubicin plus Bortezomib)
Unknown status
- Ovarian Neoplasm Epithelial
- High Grade Serous Carcinoma
- Pegylated liposomal doxorubicin plus Bortezomib
-
Seongnam Si, Gyenggi DO, Korea, Republic ofSeoul National University Bundang Hospital
Jan 12, 2020
Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Unknown status
- Ovarian Neoplasm Epithelial
- Hereditary Breast and Ovarian Cancer Syndrome
-
Beijing, Beijing, China
- +1 more
Nov 9, 2018